相关实验视频
Updated: Apr 29, 2026

06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.8K
ERRγ 阻碍神经内分泌前列腺癌的发展
Ting Li1,2,3, Catherine R Dufour4, Lingwei Han4,5
1Goodman Cancer Institute, McGill University, Montréal, Québec H3A 1A3, Canada; vincent.giguere@mcgill.ca tingli@um.edu.mo.
Genes & development
|October 29, 2025
概括
核受体ERRγ的损失驱动神经内分泌前列腺癌 (NEPC) 的进展. 恢复ERRγ功能抑制瘤生长,为这种致命的前列腺癌亚型提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 神经内分泌前列腺癌 (NEPC) 是割耐性前列腺癌 (CRPC) 的致命亚型.
- 对于CRPC向NEPC进展的分子驱动因素尚未完全理解.
- 迫切需要有效的NEPC治疗方法.
研究的目的:
- 研究核受体ERRγ在前列腺癌进展到NEPC中的作用.
- 根据ERRγ函数来确定NEPC的潜在治疗点.
主要方法:
- 使用了前列腺腺癌的Pten缺陷小鼠模型.
- 使用先进的细胞和异种移植模型来研究人类前列腺癌.
- 研究了ERRγ功能增益和功能丧失效应.
- 分析了神经内分泌转录程序和代谢重编程.
- 评估了EZH2和RET激酶的联合药理抑制.
主要成果:
- 失去ERRγ促进前列腺腺癌中神经内分泌分化.
- 功能的ERRγ获取逆转NEPC特征,抑制瘤生长,并改变新陈代谢.
- 缺少ERRγ会激活神经内分泌的转录程序.
- 结合EZH2和RET激酶抑制有效向ERRγ缺乏的NEPC细胞和器官.
结论:
- 低调ERRγ是前列腺癌从腺转化为神经内分泌转化的关键促进因素.
- 针对ERRγ缺陷造成的脆弱性,为NEPC提供了一个有前途的治疗策略.
- 药理上抑制EZH2和RET激酶是对NEPC的潜在治疗方法.
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
816
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
816
Esophageal Achalasia
38
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide...
38

